证券代码：920982 证券简称：锦波生物 公告编号：2025-185 山西锦波生物医药股份有限公司 关于拟向全资子公司增加注册资本的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、对外投资概述 （一）基本情况 根据公司战略发展规划及业务发展需要，公司拟向全资子公司锦波医学生 物材料（北京）有限公司（以下简称"锦波医学"）增资人民币 16,500 万元， 本次增资完成后锦波医学的注册资本由人民币 3,500 万元增加至人民币 20,000 万元。 （二）是否构成重大资产重组 本次交易不构成重大资产重组。 根据《上市公司重大资产重组管理办法》的相关规定，本次对外投资系对 全资子公司增资，不构成重大资产重组。 （七）投资对象是否开展或拟开展私募投资活动 本次交易标的不涉及开展或拟开展私募投资活动，不是已在中国证券投资基 金业协会登记为私募基金管理人，不会将公司主营业务变更为私募基金管理业务。 （三）是否构成关联交易 本次交易不构成关联交易。 （四）决策与审议程序 公司于 2025 年 12 月 2 ...

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 证券代码：920982 证券简称：锦波生物 公告编号：2025-184 （一）会议召开情况 1.会议召开时间：2025 年 12 月 23 日 山西锦波生物医药股份有限公司 第四届董事会第十八次会议决议公告 4.发出董事会会议通知的时间和方式：2025 年 12 月 20 日以邮件方式发出 5.会议主持人：董事长杨霞女士 6.会议列席人员：薛芳琴、兰小宾 7.召开情况合法合规的说明： 本次会议的召集、召开、审议过程符合《中华人民共和国公司法》等有关法 律、行政法规、部门规章、规范性文件及《公司章程》的规定。 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 董事陈镔、王玲玲、阎丽明、梁桐栋、邓泽林因出差或外地办公以通讯方式 参与表决。 二、议案审议情况 2.会议召开地点：公司四楼会议室 3.会议召开方式：现场加通讯 4.提交股东会表决情况： 本议案无需提交股东会审议。 （二）审议通过《关于拟向全资子公司增加注 ...

Core Viewpoint - The medical beauty sector experienced a decline of 1.37% on December 23, with Ai Meike leading the drop, while the overall market indices showed slight increases [1] Group 1: Market Performance - The Shanghai Composite Index closed at 3919.98, up 0.07% [1] - The Shenzhen Component Index closed at 13368.99, up 0.27% [1] - The medical beauty sector saw a net outflow of 64.78 million yuan from main funds, while retail investors contributed a net inflow of 39.45 million yuan [1] Group 2: Individual Stock Performance - Jinbo Biological (code: 920982) closed at 249.76, with a gain of 1.33% and a trading volume of 88,613.2 hands, totaling 218 million yuan [1] - ST Meigu (code: 000615) closed at 4.18, down 0.95% with a trading volume of 215,700 hands, totaling 9.28 million yuan [1] - Huaxi Biological (code: 688363) closed at 43.48, down 1.29% with a trading volume of 24,700 hands, totaling 108 million yuan [1] - Ai Meike (code: 300896) closed at 142.29, down 1.46% with a trading volume of 28,000 hands, totaling 400 million yuan [1] Group 3: Fund Flow Analysis - Jinbo Biological saw a main fund net inflow of 6.66 million yuan, with a main fund net ratio of 3.05% [2] - ST Meigu experienced a main fund net outflow of 1.76 million yuan, with a net inflow from retail investors of 2.50 million yuan [2] - Huaxi Biological had a main fund net outflow of 14.61 million yuan, with a retail net inflow of 6.11 million yuan [2] - Ai Meike faced a significant main fund net outflow of 48.42 million yuan, while retail investors contributed a net inflow of 30.84 million yuan [2]

Group 1 - The report highlights the performance of the North Exchange in 2025, indicating a significant rise in the North Index 50 to around 1400 points, with three distinct phases of market movement: rapid increase, oscillating rise, and a correction phase [2][12][15] - In the rapid increase phase (January 1 - March 11, 2025), the North Index 50 surged from 1,037.81 to 1,418.65 points, achieving a cumulative return of 36.70%, while the specialized index rose from 1,683.33 to 2,421.50 points, with a return of 43.85% [15][16] - The oscillating rise phase (April 7 - September 5, 2025) saw the North Index 50 increase from 1,044.07 to 1,647.01 points, yielding a cumulative return of 58.70%, and the specialized index from 1,759.64 to 2,806.39 points, with a return of 66.72% [16][17] Group 2 - The correction phase (September 15 - December 19, 2025) stabilized the North Index 50 and specialized index around 1400 and 2400 points, respectively, with the North Index 50 declining to 1,445.84 points and the specialized index to 2,440.21 points, resulting in cumulative returns of 39.32% and 44.96% [17][23] - The report emphasizes the performance of small-cap stocks, indicating that companies with market capitalizations of 0-20 billion, 20-40 billion, 40-80 billion, and above 80 billion had average returns of 54.08%, 38.60%, 18.26%, and 30.59%, respectively [26][31] - The report identifies that national and provincial-level "little giant" companies outperformed non-little giant firms, with average returns of 48.26%, 38.06%, and 39.19% for national, provincial, and non-little giants, respectively [27][29] Group 3 - The report highlights that national and provincial-level single champion companies achieved average returns of 59.27% compared to 39.61% for non-single champion companies [32][34] - In terms of industry performance, high-end equipment and new chemical materials sectors showed higher returns, with average returns of 50.20%, 28.67%, 48.49%, 40.43%, and 43.56% for high-end equipment, information technology, new chemical materials, consumer services, and biomedicine, respectively [34][36] - The report also notes that companies with new productive forces, ESG attributes, high scarcity, and high dividends had average returns of 50.49%, 48.44%, 49.14%, and 57.51%, respectively, indicating a strong performance in these categories [37][43]

Investment Rating - The report assigns an "Accumulate" rating for the beauty and personal care sector, indicating a positive outlook for the industry [6]. Core Insights - The beauty and personal care sector has experienced a significant pullback since August, with leading high-growth companies' valuations returning to 20-30x, and PEG ratios mostly below 1x, suggesting the sector is expected to bottom out [3][6]. - Lin Qingxuan is set to go public, focusing on the oil-based skincare segment, with a projected doubling of performance in the first half of 2025 [3][6]. Summary by Sections Market Performance - The beauty and personal care sector saw a decline of over 15% since August, with leading companies experiencing a valuation correction to 20-30x. The sector's maximum drawdown reached 17%, with top companies seeing declines of over 30% [6][8]. - The Shenyuan Beauty Care Index recorded a maximum increase of 19% in 2025, with key growth stocks like Ruoyuchen, Shangmei, and Maogeping achieving maximum gains of 239%, 198%, and 121% respectively [6][8]. Company Highlights - Lin Qingxuan, which is set to launch its IPO, plans to issue 13.97 million shares at an offering price of 77.77 HKD per share, corresponding to a market capitalization of 10.9 billion HKD. The company has secured cornerstone investors including Fidelity and others, with total subscriptions reaching 62 million USD [6][8]. - Lin Qingxuan's revenue for the first half of 2025 is projected at 1.05 billion CNY, reflecting a year-on-year increase of 98%, with a net profit of 182 million CNY, up 110%. The company's main product, a camellia oil essence, generated 480 million CNY in revenue, marking a 176% increase [6][8]. Investment Recommendations - The report suggests a bottom-up selection of stocks with product and channel innovations, highlighting strong growth potential in the beauty and personal care sector. Recommended stocks include: 1. High-growth brands: Ruoyuchen, Shangmei, Maogeping 2. Stable fundamentals with potential for improvement: Dengkang Oral, Shanghai Jahwa, Shuiyang, Jinbo Biological, Beitaini, Marubi, Qingsong 3. Stocks expected to bottom out: Pola, Juzibio, Lafang, Runben, Meilitiantian Medical Health, Furida, Huaxi Biological [6][7].

证券之星消息，12月19日医疗美容板块较上一交易日上涨2.13%，爱美客领涨。当日上证指数报收于 3890.45，上涨0.36%。深证成指报收于13140.22，上涨0.66%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300896 | 爱美客 | 145.80 | 2.81% | 4.06万 | | 5.8716 | | 920982 | 锦波生物 | 251.98 | 1.60% | 1.33万 | | 3.31亿 | | 000615 | *ST美谷 | 4.11 | 1.48% | 7.03万 | | 2875.42万 | | 688363 | 华熙生物 | 44.18 | 1.28% | 3.23万 | | 1.43亿 | | 代码 | 名称 | | | 主力净流入（元） 主力净占比 游资净流入（元） 游资净占比 散户净流入（元） 散户净占比 | | | | | --- | --- | --- | --- | --- | --- | ...

从资金流向上来看，当日医疗美容板块主力资金净流入6532.5万元，游资资金净流出1191.11万元，散户 资金净流出5341.39万元。医疗美容板块个股资金流向见下表： 证券之星消息，12月16日医疗美容板块较上一交易日上涨0.98%，爱美客领涨。当日上证指数报收于 3824.81，下跌1.11%。深证成指报收于12914.67，下跌1.51%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300896 | 爱美客 | 140.56 | 2.02% | 4.62万 | 6.53 Z | | 688363 | 华熙生物 | 43.29 | -0.07% | 3.98万 | 1.74亿 | | 920982 | 锦波生物 | 262.15 | -0.32% | 1.66万 | 4.44 Z | | 000615 | *ST美谷 | 4.09 | -1.45% | 5.75万 | 2369.06万 | 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备31010 ...

关于变更向不特定合格投资者公开发行股票并在北京证券交易所上市 持续督导、2025年度向特定对象发行股票保荐代表人的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带 法律责任。 山西锦波生物医药股份有限公司（以下简称"公司"）于2025年12月12日收到 保荐机构中信证券股份有限公司（以下简称"中信证券"）《关于更换保荐代表人 的函》，具体情况如下： 证券代码：920982 证券简称：锦波生物 公告编号：2025-183 山西锦波生物医药股份有限公司 中信证券作为公司向不特定合格投资者公开发行股票并在北京证券交易所上市 项目及2025年度向特定对象发行股票项目的保荐机构，其中，鉴于向不特定合格投 资者公开发行股票并在北京证券交易所上市项目处于法定持续督导期间，保荐机构 尚需履行持续督导义务，持续督导保荐代表人为邓俊、姚曜；2025年度向特定对象 发行股票项目的保荐代表人为邓俊、姚曜。现因原保荐代表人姚曜工作变动原因， 不再负责公司持续督导工作及本次向特定对象发行股票的保荐工作。为保证公司持 续督导工作及本次向特定 ...

Trading Volume and Market Activity - On December 12, the total trading volume of individual stocks on the Beijing Stock Exchange reached 1.134 billion shares, with a total transaction value of 26.973 billion yuan, a decrease of 1.332 billion yuan compared to the previous trading day [1] - Among the tradable stocks, 143 stocks closed higher, accounting for 50% of the total, while 139 stocks closed lower [1] - The stocks with the highest closing gains included Chuangyuan Xinke, Changfu Co., and Caneng Electric Power, which rose by 14.80%, 11.38%, and 11.29% respectively [1] Stock Performance Highlights - The stocks with the highest transaction values included Jinbo Biological, Xingtou Measurement Control, and Tianli Composite, with transaction values of 1.045 billion yuan, 869 million yuan, and 862 million yuan respectively [1] - A total of 76 stocks had transaction values exceeding 10 million yuan, indicating significant trading activity [1] - The highest turnover rates were observed in stocks such as Dapeng Industrial, Jingchuang Electric, and Guangdao Tui, with turnover rates of 70.76%, 45.80%, and 41.72% respectively [1] Price Movements - The stock Guangdao Tui experienced the largest decline, dropping by 21.09%, followed by Longzhu Technology and Henghe Co., which fell by 6.56% and 6.53% respectively [1] - The closing prices of notable stocks included Jinbo Biological at 275.50 yuan, Tianli Composite at 60.84 yuan, and Chuangyuan Xinke at 31.80 yuan [1][2]

证券时报·数据宝统计显示，锦波生物今日收盘价为275.50元，上涨9.02%，日换手率为7.01%，成交额 为10.40亿元，近5日该股累计上涨20.67%。 据天眼查APP显示，山西锦波生物医药股份有限公司成立于2008年03月28日，注册资本11506.534万人 民币。（数据宝） 锦波生物（920982）12月12日大宗交易平台出现一笔成交，成交量1.46万股，成交金额478.88万元，大 宗交易成交价为328.00元，相对今日收盘价溢价19.06%。该笔交易的买方营业部为中信证券股份有限公 司大连高新园区证券营业部，卖方营业部为华泰证券股份有限公司南京长江路证券营业部。 进一步统计，近1个月内该股累计发生6笔大宗交易，合计成交金额为3240.88万元。 | 成交量 | 成交金额 | 成交价格 | 相对当日收 盘价折溢价 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | （%） | | | | 1.46 | 478.88 | 328.00 | 19.06 | 中信证券股份有限公司 大连高新园区证券营 ...